Plena Global is Proud to Participate in the Canada Cannabis House at Davos

Plena Global is Proud to Participate in the Canada Cannabis House at Davos

As a side event to the World Economic Forum, the Canada Cannabis House is an unprecedented event where international industry leaders will assemble from January 22-24 in Davos, Switzerland, and Plena Global is honored to be a part of it. With all eyes on the Canadian experience of cannabis legalization, Plena SVP of Global Affairs Mike Dacks shares his thoughts and expertise in the discussion entitled “How to Build International Brands in the Cannabis Industry” on Wednesday, January 23rd.

With a variety of thought-provoking panel discussions and an exclusive interview with Israel’s 10th Prime Minister Ehud Barak, guests attending the three-day event will have the opportunity to convene with international governments and business leaders about the rapid global evolution of the cannabis industry. “I believe participating in the Canada Cannabis House at Davos is an excellent opportunity for industry leaders to connect away from the distractions of the North American markets, and explore the massive global opportunities in infrastructure, licensing, r&d and supply chain relationships that must be built across borders and regions,” says Dacks on Plena Global’s involvement in the exclusive event. In today’s modern cannabis market, Plena Global Holdings Inc. has established itself as a global leader by meeting the ever-increasing demand for reliable and affordable cGMP cannabis raw materials and API around the world.

Co-hosted by the Canadian Securities Exchange, Kapoor Kapital, and OTC Markets Group Inc., the unique CannaTech Pavilion event has invited industry thought leaders, top cannabis trade organizations and C-suite executives from around the globe to gain a comprehensive overview of investment and trading options for growth-oriented, innovative and entrepreneurial cannabis companies.

Plena is deeply rooted in its commitment to educating people on the real benefits of medical cannabis and meeting the needs of a flourishing market with cGMP grade products